A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (NCT07170150)

🧪 Interventions in This Study

• Trontinemab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (150 Sites)

Showing the first 25 of 150 sites.

• Banner Alzheimer?s Institute — Phoenix, Arizona
• Sun Valley Research Center, Inc. — Imperial, California
• Healthy Brain Clinic — Long Beach, California
• Oakland Clinical — Oakland, California
• Riverside Clinical — Riverside, California
• Cenexel California Neuroscience Research, LLC — Sherman Oaks, California
• Yale University — New Haven, Connecticut
• JEM Research LLC — Atlantis, Florida
• K2 Medical Research-Winter Garden — Clermont, Florida
• Visionary Investigators Network- Neurology Aventura — Miami, Florida
• Charter Research - Winter Park/Orlando — Orlando, Florida
• Conquest Research - Lake Nona — Orlando, Florida
• Alzheimer's Research and Treatment Center — Stuart, Florida
• CenExel iResearch, LLC — Decatur, Georgia
• Center for Advanced Research & Education — Gainesville, Georgia
• Great Lakes Clinical Trials Chicago d/b/a Flourish Research Andersonville — Chicago, Illinois
• Adams Clinical Boston — Boston, Massachusetts
• Adams Clinical Watertown — Watertown, Massachusetts
• Quest Research Institute — Farmington Hills, Michigan
• University of Nebraska Medical Center — Omaha, Nebraska
• The Cognitive and Research Center of New Jersey — Springfield, New Jersey
• IMA Clinical Research - Albuquerque — Albuquerque, New Mexico
• AD-CARE, University of Rochester Medical Center — Rochester, New York
• Summit Research Network Inc. — Portland, Oregon
• Flourish Research ? Philadelphia — Plymouth Meeting, Pennsylvania

📞 Contact the Study Coordinator

Phone: (888) 662-6728

Email: global-roche-genentech-trials@gene.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Alzheimers Disease

• Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) — Birmingham, Alabama
• Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease — Atlantis, Florida
• Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 — Birmingham, Alabama
• A Post Authorization Registry Study of Participants Treated With LEQEMBI — Vancouver, British Columbia
• A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — Birmingham, Alabama

Explore by condition: All Alzheimers Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.